Managing Symptomatic Drug-Induced Liver Injury in HIV—Hepatitis C Virus—Coinfected Patients: A Role for Interferon

摘要

Background. Human immunodeficiency virus (HIV)–infected patients with hepatitis C virus (HCV) coinfection are at increased risk for drug-induced liver injury (DILI) compared with patients with HIV infection alone. The mechanism underlying this observation is unknown. We hypothesized that interferon (IFN) would induce biochemical improvement through its anti-inflammatory properties and thereby facilitate the reintroduction of antiretroviral therapy (ART) in patients with DILI.